Skip to search formSkip to main contentSkip to account menu

custirsen

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

OGX-011

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2017
Highly Cited
2017
Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial.
Highly Cited
2017
Highly Cited
2017
Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel…
Review
2014
Review
2014
Castration-resistant prostate cancer: latest evidence and therapeutic implications
Medical oncologists who treat men with castration-resistant prostate cancer (CRPC) have seen an abundance of new agents approved… 
Review
2014
Review
2014
Clusterin: a key player in cancer chemoresistance and its inhibition
  • T. Koltai
  • OncoTargets and therapy
  • 2014
  • Corpus ID: 7322773
Clusterin is a heterodimeric disulfide-linked glycoprotein (449 amino acids) isolated in the rat prostate after castration. It is… 
Review
2014
Review
2014
Treatment options in castration-resistant prostate cancer: current therapies and emerging docetaxel-based regimens.
Review
2013
Review
2013
Potential use of custirsen to treat prostate cancer
  • C. Higano
  • OncoTargets and therapy
  • 2013
  • Corpus ID: 6788136
Over the last few years, five agents have demonstrated a survival benefit over a comparator treatment or placebo in the treatment… 
Highly Cited
2012
Highly Cited
2012
Phase I/II Trial of Custirsen (OGX-011), an Inhibitor of Clusterin, in Combination with a Gemcitabine and Platinum Regimen in Patients with Previously Untreated Advanced Non-small Cell Lung Cancer
Purpose: Clusterin (CLU), an antiapoptotic, stress-associated protein, confers resistance to therapy when overexpressed. This… 
Highly Cited
2011
Highly Cited
2011
Randomized Phase II Trial of Custirsen (OGX-011) in Combination with Docetaxel or Mitoxantrone as Second-line Therapy in Patients with Metastatic Castrate-Resistant Prostate Cancer Progressing after…
Purpose: Clusterin (CLU) is an antiapoptotic, stress-induced protein conferring treatment resistance when overexpressed. This… 
Review
2008
Review
2008
Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin for the treatment of cancer
Background: Clusterin is a stress-induced cytoprotective chaperone protein, regulated by HSF1, and functions similarly to a small… 
2008
2008
A phase II randomized study of custirsen (OGX-011) combination therapy in patients with poor-risk hormone refractory prostate cancer (HRPC) who relapsed on or within six months of 1st-line docetaxel…
5002 Background: There is no standard of care when pts with metastatic HRPC manifest disease progression (PD) after 1st-line… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)